6,7,4'-Trihydroxyisoflavone

Research use only, not for human use.

6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.

6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1, which has antioxidant, and anti-cancer activities.Molecular studies showed that 6,7,4'-THIF significantly inhibited acetylcholinesterase and thiobarbituric acid reactive substance (TBARS) activities in the hippocampus of scopolamine-induced mice.In addition, immunohistochemistry and Western blot results revealed that 6,7,4'-THIF significantly increased brain-derived neurotrophic factor (BDNF) and phosphor cAMP response element binding (CREB) in the hippocampus of mice. A single administration of 6,7,4'-THIF significantly improved scopolamine-induced cognitive dysfunction in these in vivo tests. Moreover, treatment with 6,7,4'-THIF alone enhanced learning and memory performance in the same behavioral tests. 6,7,4'-THIF improves cognitive dysfunction induced by scopolamine and enhances learning and memory by activation of the cholinergic system and the p-CREB/BDNF signaling pathway in mice.

Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppessesanchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity.Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner andinhibits CDK2 activity in HCT-116 cells.Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) . Cell Viability Assay Cell Line:HCT-116 cells Concentration:0, 12.5, 25, 50 or 100 μM Incubation Time:24, 48 or 72 hours Result:Inhibited anchorage-dependent and -independent growth of HCT-116 cells.Western Blot Analysis Cell Line:HCT-116 and DLD1 cells Concentration:0, 25, 50 or 100 μM Incubation Time:48 hours Result:Inhibited CDK1,CDK2 expression.Cell Cycle Analysis Cell Line:HCT-116 cells Concentration:0, 25, 50 or 100 μM Incubation Time:24, 48 or 72 hours Result:Induces cell cycle arrest of HCT-116 cells at S and G2/M phases.

Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system. Animal Model:Female athymic nude mice subcutaneously injected with HCT-116 cells Dosage:5 or 25 mg/kg Administration:Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days Result:Decreased tumor growth, volume and weight of HCT-116 xenografts.

——

Angiogenesis

PKC

CDK1|CDK2|PKC

——

——

17817-31-1

270.2

C15H10O5

>98% (HPLC)

DMSO:125 mg/mL (462.55 mM; Need ultrasonic)

O=C1C(C2=CC=C(O)C=C2)=COC3=CC(O)=C(O)C=C13

——

(-20℃)

With Ice Pack

≥ 2 years